MedTrace Logo

BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma

NCT07196124 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-09-29

No results posted yet for this study

Summary

This study is a single-arm, multicenter clinical trial of dose escalation and dose expansion.

Conditions

  • Multiple Myeloma Refractory

Interventions

BIOLOGICAL

BCMA/GPRC5D CAR-T

A single infusion of BCMA/GPRC5D CAR-T Injection administered intravenously.

Sponsors & Collaborators

  • Guangzhou Bio-gene Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-10
Primary Completion
2028-10-09
Completion
2028-12-09

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07196124 on ClinicalTrials.gov